Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.42 |
| ▸ | MDM4 | O15151 | 8/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3883231 | 0.99 | MDM2 (0.42) | MDM2MDM4HTR2CHTR2AHTR2B | |
| SCHEMBL3873922 | 0.85 | TRPV1 (0.51) | HTR2CHTR2AHTR2BHTR6TRPV1 | |
| SCHEMBL3872517 | 0.85 | TRPV1 (0.49) | HTR2CHTR2AHTR2BHTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3883795 | 0.84 | TRPV1 (0.48) | HTR2CHTR2AHTR2BHTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3874607 | 0.84 | TRPV1 (0.48) | HTR2CHTR2AHTR2BHTR6SMN1; SMN2 | |
| SCHEMBL3980738 | 0.76 | MEN1 (0.49) | HTR2CHTR2AHTR2BHTR6TRPV1 | |
| SCHEMBL11749065 | 0.69 | MEN1 (0.53) | TRPV1 | |
| SCHEMBL11749061 | 0.69 | MEN1 (0.53) | TRPV1 | |
| Hydrochloric Acid SCHEMBL3875713 | 0.67 | TRPV1 (0.35) | HTR2CHTR2AHTR2BHTR6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3882718 | 0.67 | TRPV1 (0.35) | HTR2CHTR2AHTR2BHTR6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550464-B2 | Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis | MITSUBISHI TANBE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | claimed |
| EP-1424326-B1 | FUSED-POLYCYCLIC COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-05-28 | — | — | EP | claimed |
| US-20070010521-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-11 | — | — | US | claimed |
| US-7153859-B2 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-26 | — | — | US | claimed |
| US-20040204418-A1 | Fused-polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| EP-1424326-A1 | FUSED-POLYCYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| US-7550475-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550476-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550464-B2 | Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis | MITSUBISHI TANBE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1424326-B1 | FUSED-POLYCYCLIC COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070010521-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070004739-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004740-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7153859-B2 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20040204418-A1 | Fused-polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1424326-A1 | FUSED-POLYCYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004740-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | MDM2 4859/4885MDM4 3368/4885HTR2C 2836/4885 |
| US-20070010521-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | MDM2 4859/4885MDM4 3368/4885HTR2C 2836/4885 |
| US-20070004739-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | MDM2 4859/4885MDM4 3368/4885HTR2C 2836/4885 |
| US-20040204418-A1 | Fused-polycyclic compounds | PDE4A, PDE4B, PDE3B | MDM2 4855/4885MDM4 3531/4885HTR2C 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.